Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Emma Kent"'
Autor:
Panagiotis Karagiannis, Federica Villanova, Debra H Josephs, Isabel Correa, Mieke Van Hemelrijck, Carl Hobbs, Louise Saul, Isioma U Egbuniwe, Isabella Tosi, Kristina M Ilieva, Emma Kent, Eduardo Calonje, Mark Harries, Ian Fentiman, Joyce Taylor-Papadimitriou, Joy Burchell, James F Spicer, Katie E Lacy, Frank O Nestle, Sophia N Karagiannis
Publikováno v:
OncoImmunology, Vol 4, Iss 11 (2015)
Emerging evidence suggests pathological and immunoregulatory functions for IgG4 antibodies and IgG4+ B cells in inflammatory diseases and malignancies. We previously reported that IgG4 antibodies restrict activation of immune effector cell functions
Externí odkaz:
https://doaj.org/article/5cf1db22e937403383ee10994dd14c28
Autor:
Angèl Link, Elena Nicod, A. Vagoras, Emma Kent, Jaime Espín, Entela Xoxi, Anna Zaremba, Inneke van de Vijver, Tatyana Benisheva, Sheela Upadhyaya, Karen Facey, Aisling O'Leary
Publikováno v:
Pharmacoeconomics
PharmacoEconomics
Facey, K M, Espin, J, Kent, E, Link, A, Nicod, E, O'Leary, A, Xoxi, E, van de Vijver, I, Zaremba, A, Benisheva, T, Vagoras, A & Upadhyaya, S 2021, ' Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments : Nusinersen and Tisagenlecleucel ', PharmacoEconomics . https://doi.org/10.1007/s40273-021-01050-5
PharmacoEconomics, Auckland : ADIS INT LTD, 2021, vol. 39, no. 9, p. 1021-1044
PharmacoEconomics
Facey, K M, Espin, J, Kent, E, Link, A, Nicod, E, O'Leary, A, Xoxi, E, van de Vijver, I, Zaremba, A, Benisheva, T, Vagoras, A & Upadhyaya, S 2021, ' Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments : Nusinersen and Tisagenlecleucel ', PharmacoEconomics . https://doi.org/10.1007/s40273-021-01050-5
PharmacoEconomics, Auckland : ADIS INT LTD, 2021, vol. 39, no. 9, p. 1021-1044
Background and Objective Enthusiasm for the use of outcomes-based managed entry agreements (OBMEAs) to manage uncertainties apparent at the time of appraisal/pricing and reimbursement of new medicines has waned over the past decade, as challenges in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8213f0ba86166a7749991059bdf8de58
http://europepmc.org/articles/PMC8260322
http://europepmc.org/articles/PMC8260322
Autor:
Pamela Brunswick, Oxana Blajkevitch, Taylor Filewood, Emma Kent, Mark C. Drever, Robert W. Elner, Dayue Shang
Publikováno v:
Journal of Chromatography A. 1693:463870
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::71332c5a60d8e0cc644f03b3e995037b
https://doi.org/10.1016/j.chroma.2023.463870
https://doi.org/10.1016/j.chroma.2023.463870
Autor:
Heather M. Moore, Wendy W. Lin, Tharu M. Fernando, Celine Lopez, Emma Kent, Karine Ellouk, Jennifer M. Giltnane
Publikováno v:
Cancer Research. 83:P6-04
BACKGROUND The cell proliferation biomarker Ki67 is expressed during every phase of the cell cycle and has long been used as a diagnostic tool for cancer prognosis, especially for hormone receptor positive breast cancer (HR+ BC). More recently, Ki67
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c56525bacecbd26b77d4e9d79f39aeec
https://doi.org/10.1158/1538-7445.sabcs22-p6-04-09
https://doi.org/10.1158/1538-7445.sabcs22-p6-04-09
Publikováno v:
Forensic Science International. 287:207-216
© 2018 Elsevier BV. This manuscript version is made available under the CC-BY-NC-ND 4.0 license:http://creativecommons.org/licenses/by-nc-nd/4.0/
The Akabori–Momotani reaction can be used to synthesise pseudoephedrine in 50% yield from N-meth
The Akabori–Momotani reaction can be used to synthesise pseudoephedrine in 50% yield from N-meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06a0bee384f440c442f3aa9d468d7cc1
https://doi.org/10.1016/j.forsciint.2018.01.023
https://doi.org/10.1016/j.forsciint.2018.01.023
Autor:
Richard Kaplan, Jonathan A. Ledermann, Philip Beale, Icon investigators, Mahesh K. B. Parmar, Monique Bertrand, Antonio Gonzalez Martin, Eric Pujade-Lauraine, Jacobus Pfisterer, Amit M. Oza, Andrew C. Embleton, Timothy J. Perren, Nana Scotto, Andrés Cervantes, Emma Kent, Gunnar B. Kristensen
Publikováno v:
Obstetrics & Gynaecology Publications
Dadun. Depósito Académico Digital de la Universidad de Navarra
instname
Gynecologic Oncology
Dadun. Depósito Académico Digital de la Universidad de Navarra
instname
Gynecologic Oncology
Objective In the randomized phase 3 ICON7 trial (ISRCTN91273375), adding bevacizumab to chemotherapy for newly diagnosed ovarian cancer significantly improved progression-free survival (PFS; primary endpoint) but not overall survival (OS; secondary e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb59e0c9c9e62879459a723743e068c9
https://ir.lib.uwo.ca/context/obsgynpub/article/1095/viewcontent/1_s2.0_S0090825818311661_main.pdf
https://ir.lib.uwo.ca/context/obsgynpub/article/1095/viewcontent/1_s2.0_S0090825818311661_main.pdf
Autor:
Thomas Paling, Emma Kent
Publikováno v:
International Journal of Technology Assessment in Health Care. 35:79-79
IntroductionManaged access arrangements (MAAs) represent a way of enabling patient access to promising treatments while collecting real world data to inform future health technology evaluations (HTE) and commissioning decisions. In July 2016, the Nat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a62ff0ef757395f6113894d1f3cb22d
https://doi.org/10.1017/s0266462319002939
https://doi.org/10.1017/s0266462319002939
Autor:
Ed, Dicks, Honglin, Song, Susan J, Ramus, Elke Van, Oudenhove, Jonathan P, Tyrer, Maria P, Intermaggio, Siddhartha, Kar, Patricia, Harrington, David D, Bowtell, Aocs Study, Group, Mine S, Cicek, Julie M, Cunningham, Brooke L, Fridley, Jennifer, Alsop, Mercedes, Jimenez-Linan, Anna, Piskorz, Teodora, Goranova, Emma, Kent, Nadeem, Siddiqui, James, Paul, Robin, Crawford, Samantha, Poblete, Shashi, Lele, Lara, Sucheston-Campbell, Kirsten B, Moysich, Weiva, Sieh, Valerie, McGuire, Jenny, Lester, Kunle, Odunsi, Alice S, Whittemore, Natalia, Bogdanova, Matthias, Dürst, Peter, Hillemanns, Beth Y, Karlan, Aleksandra, Gentry-Maharaj, Usha, Menon, Marc, Tischkowitz, Douglas, Levine, James D, Brenton, Thilo, Dörk, Ellen L, Goode, Simon A, Gayther, D P Paul, Pharoah
Publikováno v:
Oncotarget
We analyzed whole exome sequencing data in germline DNA from 412 high grade serous ovarian cancer (HGSOC) cases from The Cancer Genome Atlas Project and identified 5,517 genes harboring a predicted deleterious germline coding mutation in at least one
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::170e699b8a89d975d07e7a9ac465e429
https://pubmed.ncbi.nlm.nih.gov/28881617
https://pubmed.ncbi.nlm.nih.gov/28881617
Autor:
Emma Kent
Publikováno v:
Proceedings of the Institution of Civil Engineers - Civil Engineering. 170:2-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df21807145b47fb039ec565c9b865a09
https://doi.org/10.1680/jcien.2017.170.1.2
https://doi.org/10.1680/jcien.2017.170.1.2
Autor:
Emma Kent, Andy Alder
Publikováno v:
Proceedings of the Institution of Civil Engineers - Civil Engineering. 169:2-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::889fe891c2dc63199fce3957ae818632
https://doi.org/10.1680/jcien.2016.169.5.3
https://doi.org/10.1680/jcien.2016.169.5.3